<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical response to levamisole in 11 patients with complete <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's syndrome</z:e> was reviewed </plain></SENT>
<SENT sid="1" pm="."><plain>Nine patients responded, 3 completely and 6 partially, with reduction in the number and severity of buccal and <z:e sem="disease" ids="C0744369" disease_type="Disease or Syndrome" abbrv="">genital lesions</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In 3 patients each, <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> and gastrointestinal involvement responded to levamisole, and in 1 patient neurologic status improved </plain></SENT>
<SENT sid="3" pm="."><plain>Levamisole was purposely discontinued in 3 patients to assess its true role in disease control </plain></SENT>
<SENT sid="4" pm="."><plain>Each patient experienced a flare </plain></SENT>
<SENT sid="5" pm="."><plain>Reintroduction of therapy controlled the flare in <z:hpo ids='HP_0000001'>all</z:hpo> cases, although 1 patient subsequently relapsed while continuing therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients failed to respond </plain></SENT>
<SENT sid="7" pm="."><plain>Side effects necessitated permanent discontinuation of the drug in 2 respondent patients, but in no case did <z:hpo ids='HP_0001875'>neutropenia</z:hpo> or <z:mp ids='MP_0000334'>agranulocytosis</z:mp> develop </plain></SENT>
<SENT sid="8" pm="."><plain>These preliminary results suggest that levamisole may be useful in the therapy of the various manifestations of <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's syndrome</z:e> and that a controlled prospective study is indicated </plain></SENT>
</text></document>